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Highlights
 An increasing proportion of patients are being transplanted
for non-alcoholic steatohepatitis (NASH) in Europe.
 Hepatocellular carcinoma was more common in patients
transplanted with NASH.
 Survival in recipients with NASH is comparable to that of
other disease indications.
 Age, BMI, and advanced liver disease predicted poorer
outcomes in NASH recipients.DebashisHaldar,Barbara Kern,
JamesHodson, ..., ChristopheDuvoux,
Philip NoelNewsome,Stefan Schneeberger
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Lay summary
The prevalence of non-alcoholic fatty
liver disease has increased dramatically
in parallel with the worldwide increase
in obesity and diabetes. Its progressive
form, non-alcoholic steatohepatitis, is a
growing indication for liver transplanta-
tion in Europe, with good overall out-
comes reported. However, careful risk
factor assessment is required to main-
tain favourable post-transplant out-
comes in patients with non-alcoholic
steatohepatitis.Transplantation. This is an open access article under the CC BY license
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Background & Aims: Little is known about outcomes of liver
transplantation for patients with non-alcoholic steatohepatitis
(NASH). We aimed to determine the frequency and outcomes
of liver transplantation for patients with NASH in Europe and
identify prognostic factors.
Methods:We analysed data from patients transplanted for end-
stage liver disease between January 2002 and December 2016
using the European Liver Transplant Registry database. We
compared data between patients with NASH versus other aeti-
ologies. The principle endpoints were patient and overall allo-
graft survival.
Results: Among 68,950 adults undergoing ﬁrst liver transplan-
tation, 4.0% were transplanted for NASH – an increase from
1.2% in 2002 to 8.4% in 2016. A greater proportion of patients
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NASH.
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transplanted for NASH (39.1%) had hepatocellular carcinoma
(HCC) than non-NASH patients (28.9%, p <0.001). NASH was
not signiﬁcantly associated with survival of patients (hazard
ratio [HR] 1.02, p = 0.713) or grafts (HR 0.99; p = 0.815) after
accounting for available recipient and donor variables. Infection
(24.0%) and cardio/cerebrovascular complications (5.3%) were
the commonest causes of death in patients with NASH without
HCC. Increasing recipient age (61–65 years: HR 2.07, p <0.001;
>65: HR 1.72, p = 0.017), elevated model for end-stage liver dis-
ease score (>23: HR 1.48, p = 0.048) and low (<18.5 kg/m2: HR
4.29, p = 0.048) or high (>40 kg/m2: HR 1.96, p = 0.012) recipient
body mass index independently predicted death in patients
transplanted for NASH without HCC. Data must be interpreted
in the context of absent recognised confounders, such as pre-
morbid metabolic risk factors.
Conclusions: The number and proportion of liver transplants
performed for NASH in Europe has increased from 2002 through
2016. HCC was more common in patients transplanted with
NASH. Survival of patients and grafts in patients with NASH is
comparable to that of other disease indications.
Lay summary: The prevalence of non-alcoholic fatty liver dis-
ease has increased dramatically in parallel with the worldwide
increase in obesity and diabetes. Its progressive form, non-019 vol. 71 j 313–322
the ELTR database was used to assign diagnoses in these analy-
ses; secondary diagnoses were disregarded unless the primary
diagnosis was HCC or cryptogenic, for which the secondary
diagnosis was considered as the primary. Furthermore, patients
with a primary diagnosis of NASH and a secondary diagnosis of
ALD in the ELTR database were assigned a diagnosis of ALD for
the study.
For the purposes of this study, patients coded as having cryp-
togenic disease (ELTR database codes D10 ‘‘Cirrhosis – other cir-
rhosis specify”, D11 ‘‘Cirrhosis – cryptogenic unknown
cirrhosis” and E1 [as above] without a second diagnosis in the
ELTR) were designated as ‘‘presumed” NASH if their body mass
index (BMI) was ≥30 kg/m2, or CC if their BMI was <30 kg/m2. As
such, the NASH cohort comprised patients with ‘‘pure” NASH,
deﬁned as those coded as NASH in the ELTR database (F91:
‘‘Metabolic disease – NASH”), and those with ‘‘presumed” NASH
as described above.8–10,15,16
Recipient factors analysed included age at transplant, sex,
height, weight, BMI, blood group, primary liver diagnosis, pres-
ence of HCC, serum creatinine, serum bilirubin, international
normalized ratio (INR) and the model for end-stage liver disease
(MELD) score. Creatinine, bilirubin and INR had high frequencies
of missing data (>50%), and thus were not used as independent
variables in analyses but contributed to MELD when possible. Of
note, other metabolic risk factors including smoking, type 2 dia-
betes, hypertension, hyperlipidaemia and a prior history of
ischaemic heart disease were not included in the dataset. Donor
factors included age at death/donation, sex, BMI, blood group,
and type of donor (donation after circulatory death (DCD), dona-
tion after brainstem death, living related donor, domino donor).
Outcome domains comprised of patient and graft survival
status, re-transplant rates, duration of follow-up and causes of
death, as coded in the ELTR database. Primary causes of death
were used for analyses. Secondary, tertiary and un-coded free-
text causes of death were considered if the primary cause was
coded as other or unknown.
Only data from a patient’s ﬁrst LT were analysed.
Patient and overall allograft survival were the principle end-
points. Overall allograft survival was calculated from the date of
primary LT to the date of re-transplantation or date of death
(event) or the date of last follow-up during the period when
the transplant was still functioning (censored). Death-
censored graft survival was not reported due to the high propor-
tion of deaths from unknown causes (28.7% overall; 42.2%
NASH, 28.2% non-NASH) which may have made this outcome
Research Article Transplantationalcoholic steatohepatitis, is a growing indication for liver trans-
plantation in Europe, with good overall outcomes reported.
However, careful risk factor assessment is required to maintain
favourable post-transplant outcomes in patients with non-
alcoholic steatohepatitis.
 2019 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Introduction
The prevalence of non-alcoholic fatty liver disease (NAFLD) has
increased dramatically, in parallel with the worldwide increase
in obesity and diabetes.1,2 Approximately a quarter of the Euro-
pean adult population have NAFLD, representing an increase of
10% since 2005.3
Non-alcoholic steatohepatitis (NASH) and any associated
ﬁbrosis, confer a greater risk of liver-related morbidity and mor-
tality amongst patients with NAFLD.4 NASH is an increasingly
common indication for liver transplantation (LT), and is now
second only to alcohol-related liver disease (ALD) in the US.5
Similarly, NASH accounts for an increasing proportion of
patients undergoing LT in the UK (4% in 1995; 12% in 2013).6
However, pan-European data to describe the burden of NASH
on transplantation services are lacking.
Given the frequent co-existence of obesity, diabetes and
related comorbidities, patients with NASH requiring LT are con-
sidered to be at a higher risk.7 In contrast to the US,8–10 Euro-
pean reports of post-transplant outcomes of NASH have been
limited to single-centre datasets.11 In the absence of well-
validated contraindications it remains a challenge to effectively
risk-stratify patients with NASH being considered for LT.7
We have undertaken a comprehensive analysis of LT using a
prospectively updated pan-European database (n = 68,950) to
determine the frequency and outcomes of patients transplanted
for NASH. Building on this assessment, we have identiﬁed vari-
ables that predict a risk of poorer clinical outcome following LT
for NASH.
Patients and methods
Study population
We performed a retrospective cohort analysis of all adult
patients (>18 years old) who underwent primary LT for chronic
liver disease between 1 January 2002 and 31 December 2016
using the European Liver Transplant Registry (ELTR) database.
A study request was reviewed and approved by the ELTR data
subject to informative censoring.
For the purpose of survival outcome analyses and cause of
death analyses, patients were subdivided into cohorts deﬁned
by the presence or absence of concomitant HCC.
The primary comparison of interest was between patients
transplanted for NASH and those transplanted for other indica-
tions (non-NASH).committee. The ELTR prospectively collects LT data from 174
centres in 33 countries and ensures data quality and validity
by annual audit and cross checking with key European organ
sharing organisations as previously described.12–14
Data were analysed for patients transplanted for ALD, hepati-
tis C virus infection (HCV), hepatitis B virus infection (HBV),
autoimmune liver disease (AiLD) (including primary sclerosing
cholangitis, primary biliary cholangitis and autoimmune
hepatitis), cryptogenic cirrhosis (CC), NASH and ‘‘other” includ-
ing non-B, non-C chronic viral hepatitis, polycystic liver disease,
Wilson’s disease, hereditary haemochromatosis and alpha-1-
antitrypsin deﬁciency. The cohort included patients who had
hepatocellular cancer (HCC) on the background of these chronic
liver diseases (ELTR database code E1: ‘‘Cancers – Hepatocellu-
lar carcinoma, cirrhosis”). The primary liver diagnosis stated in314 Journal of Hepatology 2Statistical analysis
Statistical analyses were performed using IBM SPSS Statistics for
Windows version 24 (IBM Corp., Armonk, N.Y., USA), with p val-
ues of <0.05 deemed signiﬁcant throughout.
Parametric continuous variables were summarised with
means and standard deviations, and groups compared by inde-
pendent Student’s t test, whereas non-parametric continuous
variables were summarised by median and interquartile range,
and groups compared by Mann-Whitney U test. Categorical019 vol. 71 j 313–322
variables were summarised with frequencies and percentages,
and groups compared by chi-squared test.
Survival outcomes were compared between groups using
Kaplan-Meier curves and log-rank tests. Hazard ratios were cal-
culated using univariable Cox regression models. Multivariable
Cox regression models were produced to determine whether
NASH was independently predictive of patient outcome, after
accounting for other confounding factors. A backwards stepwise
approach was used to select factors for inclusion in the ﬁnal
model, whereby variables with a signiﬁcance of p >0.10 were
iteratively excluded from the input model. All available and clin-
ically relevant factors were included in the input models. Where
NASH was excluded due to non-signiﬁcance, it was added into
the ﬁnal model alongside the factors identiﬁed as signiﬁcant by
the stepwise procedure. The analysis was then repeated for the
subgroup of patients transplanted for NASH, to identify indepen-
dent predictors of patient survival in this cohort.
For the purposes of Cox regression analyses, continuous vari-
ables were converted to categorical fractions based on conven-
tional thresholds (e.g. World Health Organization classiﬁcation
of BMI), or to yield relatively equal numbers of patients in each
bracket (in the absence of a widely accepted convention).
Hazard ratios (HR) from regression analyses were expressed rel-
ative to a reference category deﬁned either by the group that
was closest to physiological normal, the group estimated to
have the lowest associated mortality or the largest group
(HR = 1). Speciﬁcally, for the model that was produced to iden-
tify independent predictors of patient survival in patients with
NASH, risk was assigned against a recipient BMI of 25–30
kg/m2 (n = 233), rather than 18.5–25 kg/m2 (n = 71) due to there
being signiﬁcantly fewer patients in that bracket, and the recog-
nised curvilinear association between BMI and mortality,
whereby the perceived lowest risk has shifted to a value
between 25 and 30 kg/m2 in more recent years.17
vs. 25.8 kg/m2, p <0.001). HCC was more common in recipients
transplanted for NASH (39.1% vs. 28.9%, p <0.001). Moreover,
the proportion of patients with underlying NASH amongst those
transplanted with HCC increased from 1.3% in 2002–2004, to
8.3% in 2014–16 (p <0.001) (Fig. S1). Patients with NASH
received organs from donors who were marginally older (med-
Excluded = 28,900
• <18 years
• 2nd and subsequent LT
• Multi-organ Tx
• Acute liver failure
• HCC in the absence of 
  underlying CLD
• Non-HCC malignancy
NASH
2,741
Non-NASH
66,209
All liver transplants (LT) in ELTR region
Jan 2002 → Dec 2016
68,950
97,850
Pure NASH
Patients coded as
NASH in ELTR database
1,171
Presumed NASH
Patients coded as CC
with a BMI ≥30 kg•m-2
1,570
ALD: 22,226
HCV: 16,127
AiLD: 9,300
HBV: 7,337
CC: 7,009
Other: 4,210
Fig. 1. Flow chart of case selection from the ELTR database. AiLD,
autoimmune liver disease; ALD, alcohol-related liver disease; CC, cryptogenic
cirrhosis; CLD, chronic liver disease; ELTR, European Liver Transplant
Registry; HBV, hepatitis B virus infection; HCC, hepatocellular carcinoma;
HCV, hepatitis C virus infection; NASH, non-alcoholic steatohepatitis.
NASH
ALD
HCV
AiLD
HBV
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Fig. 2. Trends of annual primary liver transplants performed for different
indications in the ELTR region. AiLD, autoimmune liver disease; ALD,
alcohol-related liver disease; CC, cryptogenic cirrhosis; ELTR, European Liver
Transplant Registry; HBV, hepatitis B virus infection; HCV, hepatitis C virus
infection; NASH, non-alcoholic steatohepatitis. (This ﬁgure appears in colour
on the web.)
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basis. However, 3 key variables had a signiﬁcant number of
missing values – MELD (31.4%), recipient BMI (33.7%), and
donor BMI (30.2%). We ensured maximal case inclusion in the
multivariable analyses by including the cases with the missing
values by assigning them to a separate ‘‘missing” category.
The frequencies of deaths due to speciﬁc causes were appor-
tioned relative to the total number of deaths in patients trans-
planted for a speciﬁc indication. Cause-speciﬁc survival analyses
were then performed using univariable Cox regression models,
with comparisons between NASH and non-NASH recipients.
Results
Prevalence of NASH as an indication for liver transplantation
over time
After exclusions, 68,950 patients underwent a primary LT for
chronic liver disease in the study period (Fig. 1). NASH was
the primary indication in 2,741 patients (4.0%), and ALD was
the most common indication (22,226; 32.2%). The proportion
of transplants performed for patients with NASH increased sig-
niﬁcantly over time from 1.2% in 2002 to 8.4% in 2016 (p <0.001)
(Fig. 2, Table S1).
Characteristics of transplant recipients and donors
In comparison to patients transplanted for other indications
(Table 1), recipients with NASH were older (median: 60 vs.
55 years, p <0.001) and had a greater BMI (mean: 32.6 kg/m2
ian: 53 vs. 52 years, p = 0.030), more likely to be male (62.3% vs.
57.6%, p <0.001) and of a greater BMI (26.9 kg/m2 vs. 25.5 kg/m2,
p <0.001) and received more DCD organs (6.6% vs. 2.6%,
Journal of Hepatology 2019 vol. 71 j 313–322 315
Table 1. Comparison of donor and recipient factors in patients trans-
planted for NASH and non-NASH indications.
NASH
n = 2,741
Non-NASH
n = 66,209
Recipient characteristics
Age, years, median (IQR)** 60 (54–64) 55 (48–61)
Sex, male, % 71.1 72.1
Blood group, %
A 43.6 43.6
AB 5.8 5.6
B 13.0 12.7
O 37.6 38.1
BMI, kg/m2, mean (SD)** 32.6 (4.6) 25.8 (4.4)
MELD, median (IQR) 16 (12–21) 16 (12–22)
HCC, % ** 39.1 28.9
Donor characteristics
Age, median (IQR)* 53 (39–61) 52 (37–64)
Sex, male, %** 62.3 57.6
Blood group, %
A 41.8 42.7
Research Article TransplantationAB 4.5 4.2
B 11.2 11.7
O 42.5 41.4
BMI, kg/m2, mean (SD)** 26.9 (4.8) 25.5 (4.3)
Type of donor, %**
DBD 84.6 90.4
DCD 6.6 2.6
Domino 0.8 1.0
Living 8.0 6.1p <0.001). However, after adjusting for the increase in use of
DCD organs over time, the rates of DCD use were similar in
transplants for NASH and non-NASH indications (odds ratio
[OR] 1.53; 0.21–11.11; p = 0.677; Table S2). Subgroup analyses
divided by patients with and without HCC identiﬁed similar
recipient and donor differences between NASH and non-NASH
groups (Table S3).
Patient survival outcomes after liver transplantation
There was no signiﬁcant difference in post-LT patient survival
between NASH and non-NASH recipients (Fig. 4), either for
recipients without (HR 1.10; 95% CI 0.99–1.22; Table 2) or with
HCC (HR 1.09; 95% CI 0.97–1.23; Table S4). Amongst those with-
out HCC, recipients with NASH (n = 1,667) had equivalent post-
LT survival to patients with ALD (n = 17,505; HR 0.95; 95% CI
0.85–1.06) and better survival than those with HCV (n = 9,007;
HR 1.27; 95% CI 1.14–1.42; p <0.001) (Table 2, Fig. 3A). For those
with HCC, survival in recipients with NASH (n = 1,073) was mar-
ginally worse than ALD (n = 4,715; HR 0.87; 95% CI 0.76–0.99;
p = 0.034), but was similar to HCV (n = 7,114; HR 1.07; 95% CI
0.94–1.21) and CC (n = 3,229; HR 0.93; 95% CI 0.81–1.06)
(Table S4, Fig. 3B).
On multivariable Cox regression, several recipient and donor
characteristics were found to be signiﬁcantly associated with
Values in bold denote signiﬁcance. *p <0.05; **p <0.001. BMI, body mass index; DBD,
donation after brainstem death; DCD, donation after circulatory death; HCC, hep-
atocellular carcinoma; MELD, model for end-stage liver disease; NASH, non-alco-
holic steatohepatitis.
Parametric continuous variables were summarised with means and standard
deviations, and groups compared by independent Student’s t test, whereas non-
parametric continuous variables were summarised by median and interquartile
range, and groups compared by Mann-Whitney U test. Categorical variables were
summarised with frequencies and percentages, and groups compared by chi-
squared test.
316 Journal of Hepatology 2Table 2. Recipient and donor factors that influence patient survival in
transplant recipients without HCC.
Univariable Multivariable
HR (95% CI)
Recipient characteristics
NASH (vs. non–NASH) 1.10 (0.99–1.22) 0.97 (0.86–1.09)
Cirrhosis aetiology Overall** n.a.
NASH 1.00
ALD 0.95 (0.85–1.06)
HCV 1.27 (1.14–1.42)**
AiLD 0.62 (0.56–0.70)**
HBV 0.68 (0.60–0.77)**
CC 1.01 (0.90–1.14)
Other 0.70 (0.62–0.80)**
Age (years) Overall** Overall**
≤45 1.00 1.00
46–55 1.24 (1.18–1.31)** 1.24 (1.18–1.31)**
56–60 1.46 (1.38–1.55)** 1.49 (1.41–1.59)**
61–65 1.74 (1.64–1.85)** 1.78 (1.67–1.89)**
>65 1.94 (1.80–2.09)** 2.04 (1.89–2.20)**
Sex, male 1.12 (1.07–1.16)** 1.11 (1.06–1.15)**
MELD Overall** Overall**
≤11 1.00 1.00
>11, ≤14 0.97 (0.89–1.07) 0.98 (0.89–1.07)
>14, ≤18 0.99 (0.91–1.07) 1.02 (0.94–1.11)
>18, ≤23 1.00 (0.92–1.09) 1.05 (0.96–1.15)
>23 1.48 (1.37–1.60) 1.52 (1.40–1.64)**
Missing value 1.15 (1.07–1.24) 1.22 (1.12–1.33)**
Blood group Overall Overall*
A 1.00 1.00
AB 0.98 (0.90–1.06) 1.18 (1.01–1.38)*
B 0.99 (0.94–1.05) 1.12 (0.95–1.31)
O 1.00 (0.96–1.04) 0.94 (0.84–1.07)
BMI (kg/m2) Overall** Overall**
≤18.5 1.20 (1.06–1.36)* 1.34 (1.18–1.52)**
>18.5, ≤25.0 1.00 1.00
>25.0, ≤30.0 1.00 (0.95–1.06) 0.95 (0.90–1.01)
>30.0, ≤35.0 1.09 (1.02–1.17)* 1.04 (0.97–1.12)
>35.0, ≤40.0 1.09 (0.96–1.23) 1.06 (0.93–1.21)
>40.0 1.35 (1.10–1.67)* 1.35 (1.09–1.67)*
Missing value 1.02 (0.97–1.07) 1.04 (0.98–1.11)
Donor characteristics
Age (years) Overall** Overall**
≤34 1.00 1.00
35–47 1.19 (1.13–1.27)** 1.16 (1.09–1.23)**
48–57 1.30 (1.22–1.37)** 1.25 (1.18–1.33)**
58–67 1.45 (1.37–1.54)** 1.38 (1.29–1.47)**
>68 1.63 (1.54–1.73)** 1.52 (1.43–1.62)**
Sex, male 0.99 (0.95–1.03) not in ﬁnal model
Blood group Overall Overall*
A 1.00 1.00
AB 0.91 (0.83–1.00) 0.82 (0.68–0.97)*
B 0.96 (0.91–1.02) 0.90 (0.76–1.06)
O 1.02 (0.98–1.06) 1.07 (0.95–1.21)
BMI (kg/m2) Overall** Overall**
≤18.5 0.92 (0.80–1.06) 0.91 (0.79–1.06)
>18.5, ≤25.0 1.00 1.00
>25.0, ≤30.0 1.10 (1.05–1.15)** 1.02 (0.97–1.07)
>30.0, ≤35.0 1.09 (1.01–1.18)* 1.02 (0.94–1.11)
>35.0, ≤40.0 1.10 (0.95–1.28) 1.02 (0.88–1.19)
>40.0 0.89 (0.69–1.15) 0.85 (0.66–1.10)
Missing value 0.92 (0.88–0.96) 0.85 (0.80–0.90)**
Type of donor Overall** Overall**
DBD 1.00 1.00
DCD 0.68 (0.59–0.79)** 0.73 (0.62–0.85)**
Domino 1.20 (1.00–1.23) 1.20 (0.99–1.45)
Living 1.14 (1.05–1.23)** 1.43 (1.31–1.56)**
Other variables
Re-transplant 1.76 (1.67–1.86)** 1.80 (1.71–1.91)**
019 vol. 71 j 313–322
post-LT survival (Table 2, Table S4). Upon adjusting for these
factors, NASH was not found to be a signiﬁcant independent
predictor of patient survival, either in patients without (HR
0.97; 95% CI 0.86–1.09) or with (HR 1.10; 95% CI 0.97–1.24)
HCC. Combining the HCC groups to analyse the cohort as a
whole returned similar results (HR 1.02; 95% CI 0.93–1.11)
(Fig. S2 panel A, Table S5).
28.2%; overall = 28.7%).
In recipients without HCC (Table S7), infection (n = 86,
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Table 2. (Continued).
Univariable Multivariable
HR (95% CI)
Era of transplant Overall** Overall**
2002–2004 1.00 1.00
2005–2007 1.05 (0.99–1.10) 1.03 (0.98–1.09)
2008–2010 1.13 (1.07–1.19)** 1.07 (1.00–1.13)*
2011–2013 1.00 (0.94–1.06) 0.93 (0.87–0.99)*
2014–2016 0.87 (0.80–0.93)** 0.81 (0.75–0.89)**
The ﬁnal multivariable models based on 47,040 patients. Values in bold denote
signiﬁcance. *p <0.05; **p <0.001. AiLD, autoimmune liver disease; ALD, alcohol-
related liver disease; BMI, body mass index; CC, cryptogenic cirrhosis; DBD, dona-
tion after brainstem death; DCD, donation after circulatory death; HBV, hepatitis B
virus infection; HCC, hepatocellular carcinoma; HCV, hepatitis C virus infection; HR,
hazard ratio; MELD, model for end-stage liver disease; NASH, non-alcoholic
steatohepatitis.
Hazard ratios were calculated using uni- and multivariable Cox regression models.
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Fig. 3. Survival analysis for patients undergoing primary liver transplantat
without (A), and with (B) HCC (log-rank: p <0.001 for both). AiLD, autoimmune
European Liver Transplant Registry; HBV, hepatitis B virus infection; HCV, hep
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On univariable analysis, post-LT graft survival (overall allograft
survival) for recipients with NASH was comparable to those
with non-NASH indications amongst patients without (HR
1.06; 95% CI 0.96–1.17) and with HCC (HR 1.02; 95% CI 0.91–
1.15) (Fig. 5, Table S6). Analysing the cohort as a whole returned
consistent results (HR 1.06; 95% CI 0.98–1.14) (Fig. S2, Table S5).
Upon adjusting for signiﬁcant determinants in multivariable
Cox regression analyses (Tables S5, S6), NASH was not found to
be a signiﬁcant independent predictor of graft survival, either in
patients without (HR 0.98; 95% CI 0.88–1.09), with (HR 1.02;
95% CI 0.90–1.15), or independent of HCC (HR 0.99; 95% CI
0.91–1.08).
Causes of death after liver transplantation
Of patients who died after LT for NASH (n = 631) and non-NASH
(n = 16,989) indications, a signiﬁcant proportion died from
unknown causes (NASH: n = 266, 42.2%; non-NASH: n = 4,799,24.0%), and cardio/cerebrovascular complications (n = 19, 5.3%)
comprised the top 2 known causes of death in patients trans-
planted for NASH. Infection (n = 2,512, 21.6%; HR 1.15; 95% CI
0.92–1.42; p = 0.216) and cardio/cerebrovascular complications
(n = 937, 8.1%; HR 0.70; 95% CI 0.44–1.10; p = 0.123) were also
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(blood group) characteristics were found to be associated with
post-LT survival (Table 3). Subsequent multivariable Cox regres-
sion modelling revealed that older recipient age (61–65 years:
HR 2.07; 95% CI 1.39–3.08; >65 years: HR 1.72; 95% CI 1.10–
2.71; relative to ≤45 years), and MELD score >23 (HR 1.48; 95%
CI 1.04–2.30; relative to ≤11) carried an increased risk of
post-LT mortality. In addition, eccentric recipient BMI was also
associated with poorer post-LT survival; an effect that was more
pronounced at the extremes (≤18.5 kg/m2: HR 4.29; 95% CI 1.01–
18.21; 18.5–25 kg/m2: HR 2.24; 95% CI 1.27–3.96; >40 kg/m2: HR
1.96; 95% CI 1.16–3.32; relative to 25–30 kg/m2). Male recipient
gender (HR 0.79 (0.63–0.98); p = 0.031), and blood group B donor
organs (HR 0.37; 95% CI 0.22–0.63; relative to blood group A)
offered a comparative survival advantage.
For patients with NASH and concomitant HCC, none of the
available variables were found to be signiﬁcantly associated
with survival on either univariable or multivariable analyses
(Table S9).
Discussion
This study ﬁnds the proportion of transplants for patients with
NASH has risen to now account for 8.4% of annual transplants in
Europe, and reﬂects rates published from national datasets.18,19
The trends are in keeping with those seen in the US where NASH
accounts for more than 18% of transplants.8,10,20,21 The magni-
tude of the impact of NASH on transplant services in the US
may forecast the future burden in Europe in heed of the pro-
jected rise of obesity across the continent.1,2,22 However, wide
intra-continental variations in risk factor proﬁles may limit
the local applicability of pan-European data.23,24 Further to
the effect of risk factors, a greater awareness of NASH, and
greater conﬁdence amongst transplant physicians to make a
diagnosis based on phenotypic associations may also contribute
to the greater proportion of transplants.25 However, the effects
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Fig. 4. Survival analysis for patients with and without HCC undergoing
primary LT for NASH and non-NASH indications. Kaplan-Meier analysis
demonstrated no signiﬁcant survival differences between patients trans-
planted for NASH and non-NASH indications amongst those without HCC
(log-rank: p = 0.081) or with HCC (log-rank: p = 0.155). There is a signiﬁcant
difference between patients transplanted with and without HCC overall (log-
Research Article Transplantationmajor causes of death in recipients transplanted for non-NASH
indications, occurring at similar rates to those observed in
NASH. There was a notable excess of death from extrahepatic
(non-HCC) solid organ malignancy in those transplanted for
ALD (n = 603, 12.9% vs. n = 9, 2.5%), and recurrent disease in
those transplanted for HCV (n = 651, 21.5% vs. n = 2, 0.6%), com-
pared to NASH recipients. These are reﬂected in the consider-
ably lower risk of death from extrahepatic malignancy (HR
0.41; 95% CI 0.21–0.79; p = 0.008) and recurrent primary liver
disease (HR 0.08; 95% CI 0.02–0.33; p <0.001) in NASH than in
pooled non-NASH recipients.
Amongst patients with concomitant HCC (Table S8), recurrent
HCC (n = 53, 19.5%), infection (n = 28, 10.3%) and extrahepatic
solid organ (non-HCC) malignancy (n = 18, 6.6%) were the top 3
causes of death in patients transplanted for NASH. All 3 were also
prominent causes of death in those transplanted for other indica-
tions, although there was again a notable excess risk of death
from recurrence of primary (non-malignant) liver pathology in
those transplanted for HCV (n = 468, 20.8%) and ALD (n = 85,
6.9%) compared to NASH recipients (n = 6, 2.2%; p <0.001).
Factors that influence overall survival in patients who are
transplanted for NASH
For patients transplanted for NASH in the absence of HCC, a num-
ber of recipient (age, sex, blood group, BMI, MELD) and donor
rank: p <0.001). HCC, hepatocellular carcinoma; LT, liver transplant; NASH,
non-alcoholic steatohepatitis. (This ﬁgure appears in colour on the web.)318 Journal of Hepatology 2of ascertainment bias in our study are unlikely to be signiﬁcant
in the absence of a commensurate decrease in transplants per-
formed for CC.
There remains controversy in the way large databases estab-
lish diagnoses of NASH and CC.25 In keeping with other large
database studies, and to facilitate meaningful comparisons
between datasets, we have chosen CC patients with a BMI
>30 kg/m2 as our presumed NASH cohort.8–10,15,16 We acknowl-
edge that ascites and oedema contribute to the BMI and are not
corrected for in the ELTR, though this is also a limitation of using
other large registry databases.8 Of our NASH study cohort, 57.3%
were ‘‘presumed NASH” which is comparable to data from the
US; between 45.2%8 and 67.5%9 of the NASH cohorts using the
United Network of Organ Sharing (UNOS) database were ‘‘pre-
sumed NASH”. However, the differences in the characteristics
and outcomes between pure and presumed NASH (Table S10,
Figs. S3, S4 and S5) highlight that NASH patients are still a
heterogeneous population and systematically identifying high
and low risk subsets based on recipient and donor characteris-
tics as highlighted in Table 3, is of critical importance.
A greater proportion of recipients with NASH were trans-
planted for HCC than non-NASH recipients (Table 1). Our ﬁnd-
ings were in keeping with a recent analysis of the US
Scientiﬁc Registry of Transplant Recipients database,26 in which
the authors describe a 7.7-fold increase in the prevalence of
NASH in patients transplanted for HCC between 2002 and
2016. A number of studies have suggested that patients with019 vol. 71 j 313–322
NASH are at greater risk of developing HCC,16,21,27 owing partly
to the risks associated with obesity and insulin resistance.28–30
NASH-related HCC is major worldwide concern and left
unchecked may offset the anticipated declines in primary liver
cancer through the control of HBV and HCV.31
Amongst the NASH cases, there was a difference in the rate of
HCC between the pure NASH (28.5%) and presumed NASH
(47.1%) cohorts (Table S10), due to incorporating the orphan
E1 ELTR code (Cancers – Hepatocellular carcinoma, cirrhosis;
no secondary diagnosis) in to the cryptogenic cohort.8 The rate
of HCC in CC (at the exclusion of obese patients) was 46.1%
(Table S11).
As with other registry studies, readers of our data should be
mindful of the potential inﬂuence of missing data points,
despite the vast number of cases included in the study. As
described in our Methods, a signiﬁcant proportion of cases in
our dataset had missing data for one of MELD, recipient BMI
or donor BMI. There were statistically signiﬁcant differences in
patient characteristics between cases with and without missing
data points (Table S12). We utilised a ‘‘missing-indicator”
method to maximally utilise the available cases and minimise
any loss of statistical power in our multivariable analyses. We
compared patient survival in those with available data against
those with missing data. The cases with a missing recipient
BMI did not confer a bias to overall patient survival (univariable
Cox regression; HR 1.01; 95% CI 0.98–1.04; p = 0.485) compared
to cases with available values. Cases with missing MELD (HR
BA
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95% CI 0.87–0.93; p <0.001) did carry a weighted risk, although
the effect was small. Moreover, we compared multivariable
models using the missing-indicator method and an ‘‘available
case analysis” method whereby only cases without missing
observations are included, and we found no signiﬁcant differ-
ences to key outcomes (Tables S13, S14). The inﬂuence of the
incomplete data is a recurrent limitation of registry database
studies and although different statistical methods to account
for the effect of missing data are widely used, they each carry
an inherent bias. Best practice on the statistical methods should
be incorporated across registries and ideally stated in the stan-
dard operating procedures of registries.
There were no signiﬁcant differences in post-LT deaths due
to infection and cardio/cerebrovascular events between NASH
and non-NASH recipients without HCC. Conclusions drawn from
these data should be tempered in consideration of the 28.7% of
cases in which the causes of death were unknown. However, the
loss of data quality with duration of follow-up is pervasive to
large databases; an analysis of the UNOS database noted that
24% of deaths that occurred 5 years or later after transplantation
were from unknown causes.32 The size of the database cohorts
may allow for a higher tolerability towards missing data points,
but it remains a limitation. By comparison, a recent meta-
analysis of 6 single- and two-centre studies demonstrated an
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Research Article TransplantationTable 3. Recipient and donor factors that significantly affect post-
transplant survival in patients transplanted for NASH without HCC.Univariable MultivariableHR (95% CI)
Recipient characteristics
Age (years) Overall* Overall**
≤45 1.00 1.00
46–55 1.17 (0.79–1.76) 1.31 (0.87–1.98)
56–60 1.08 (0.71–1.62) 1.23 (0.81–1.87)
61–65 1.71 (1.16–2.52)* 2.07 (1.39–3.08)**
>65 1.50 (0.96–2.33) 1.72 (1.10–2.71)*
Sex, male 0.74 (0.60–0.92)* 0.79 (0.63–0.98)*
MELD Overall** Overall**
≤11 1.00 1.00
>11, ≤14 0.96 (0.63–1.48) 1.03 (0.66–1.62)
>14, ≤18 0.65 (0.43–0.98)* 0.66 (0.44–1.06)
>18, ≤23 0.68 (0.44–1.05) 0.71 (0.47–1.15)
>23 1.41 (0.97–2.05) 1.48 (1.04–2.30)*
Missing value 0.83 (0.52–1.32) 0.93 (0.57–1.51)
Blood group Overall* not in ﬁnal model
A 1.00
AB 0.84 (0.53–1.33)
B 0.56 (0.37–0.85)*
O 1.02 (0.82–1.27)
BMI (kg/m2) Overall* Overall*
≤18.5 2.58 (0.62–10.72) 4.29 (1.01–18.21)*
>18.5, ≤25.0 1.98 (1.13–3.47)* 2.24 (1.27–3.96)*
>25.0, ≤30.0 1.00 1.00
>30.0, ≤35.0 1.22 (0.85–1.74) 1.38 (0.95–2.01)
>35.0, ≤40.0 1.38 (0.92–2.08) 1.43 (0.93–2.18)
>40.0 1.92 (1.15–3.18)* 1.96 (1.16–3.32)*
Missing value 0.89 (0.41–1.92) 1.13 (0.49–2.63)
Donor characteristics
Age (years) Overall not in ﬁnal model
≤45 1.00
46–55 1.15 (0.82–1.62)
56–60 1.15 (0.83–1.59)
61–65 1.20 (0.85–1.69)
>65 1.28 (0.88–1.84)
Sex, male 0.97 (0.78–1.20) not in ﬁnal model
Blood group Overall* Overall*
A 1.00 1.00
AB 0.83 (0.49–1.41) 0.99 (0.58–1.70)
B 0.39 (0.23–0.65)** 0.37 (0.22–0.63)**
O 1.05 (0.85–1.31) 1.06 (0.85–1.32)
BMI (kg/m2) not in ﬁnal model
≤18.5 1.85 (0.59–5.83)
>18.5, ≤25.0 1.13 (0.89–1.43)
>25.0, ≤30.0 1.00
>30.0, ≤35.0 0.98 (0.70–1.36)
>35.0, ≤40.0 0.69 (0.34–1.40)
>40.0 1.15 (0.54–2.45)
Missing value 0.73 (0.44–1.20)
Type of donor Overall not in ﬁnal model
DBD 1.00
DCD 0.79 (0.47–1.33)
Domino 1.16 (0.29–4.64)
Living 1.45 (1.02–2.05)
Other variables
Era of transplant Overall n.a.
2002–2004 1.00
2005–2007 0.90 (0.59–1.37)
2008–2010 1.18 (0.79–1.76)
2011–2013 1.09 (0.72–1.63)
2014–2016 1.13 (0.74–1.71)The ﬁnal multivariable models based on 1,628 patients. Values in bold denote sig-
niﬁcance. *p <0.05; **p <0.001. BMI, body mass index; DBD, donation after brain-
stem death; DCD, donation after circulatory death; HCC, hepatocellular carcinoma;
HR, hazard ratio; MELD, model for end-stage liver disease; NASH, non-alcoholic
steatohepatitis.
Hazard ratios were calculated using uni- and multivariable Cox regression models.320 Journal of Hepatology 2NASHwas not found to be an independent predictor of patient
or graft survival. These results add to a growing body of evidence
that suggest current practice in patient selection and peri-
operative care results in acceptable outcomes for such patients,
and reﬂect good utility of donor organs.6,10,20 Nevertheless, our
ﬁndings demand scrutiny of assessing transplant risk based on
recipient age and BMI. The risk attributed to older recipients is
particularly pertinent as a growing proportion of transplants
are being performed on elderly recipients in both the US and
Europe.33 Moreover, the risk carried by recipients with lower
BMI may reﬂect the independent effects of a catabolic and sar-
copenic phenotype.34 However, the associations at both
extremes of BMI are based on relatively few patients (n = 77 for
BMI ≤25 kg/m2; n = 92 for BMI >40 kg/m2, cp. n = 233 for BMI
25–30 kg/m2). Critical variables including pre-LT comorbidities,
and in particular components of metabolic syndrome, may have
inﬂuenced prognostic determinants in our analysis and signiﬁ-
cantly added to the power of our model.11,35 None of our mea-
sured variables were found to be associated with post-LT
mortality in recipients with HCC, which suggests that HCC-
speciﬁc factors that reﬂect the burden of disease are likely to have
a critical inﬂuence onpost-transplant outcomes.36 Tumour speci-
ﬁc factors have only been collected by the ELTR since 2007, and a
dedicated study exploring the inﬂuence of these factors on post-
transplant outcomes has recently been published.37
Large databases such as ELTR and UNOS were designed to
facilitate research but have to compromise between the practi-
calities of ensuring data collection and the desire to capture rel-
evant data ﬁelds. Technological developments to optimise data
collection and periodic review of collected ﬁelds in response to
evolving knowledge comprise potential solutions. Moreover,
harmonisation of data ﬁelds across different registries would
allow meaningful comparisons between datasets.
In summary, we report a year-on-year increase in the num-
ber of LTs performed for NASH in the ELTR region since 2002.
The proportion of transplants done for NASH with concomitant
HCC is rising, reﬂecting the widely acknowledged association of
NASH with HCC. NASH was not an independent predictor of
post-LT patient and graft survival. Nevertheless, careful assess-
ment and selection of patients will be critical to maintain
acceptable survival in those transplanted for NASH, with speci-
ﬁc scrutiny of female patients, recipients over the age of 60,
those with advanced liver disease (MELD >23) and particularly
patients with extreme high or low BMI.
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